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Organic anion transporter 2
transcript variant 1 shows broad
ligand selectivity when expressed in
multiple cell lines
Adam G. Hotchkiss, Liam Berrigan and Ryan M. Pelis*
Department of Pharmacology, Dalhousie University, Halifax, NS, Canada
Organic anion transporter 2 (OAT2) is likely important for renal and hepatic drug
elimination. Three variants of the OAT2 peptide sequence have been described –
OAT2 transcript variant 1 (OAT2-tv1), OAT2 transcript variant 2 (OAT2-tv2), and OAT2
transcript variant 3 (OAT2-tv3). Early studies helping to define the ligand selectivity of
OAT2 failed to identify the variant used, and the studies used several heterologous
expression systems. In preliminary studies using OAT2-tv1, we failed to observe
transport of several previously identified substrates, leading us to speculate that ligand
selectivity of OAT2 differs with variant and/or heterologous expression system. The
purpose was to further investigate the ligand selectivity of the OAT2 variants expressed
in multiple cell types. We cloned OAT2-tv1 and OAT2-tv2, but were unsuccessful at
amplifying mRNA for OAT2-tv3 from human kidney. OAT2-tv1 and OAT2-tv2 were
individually expressed in human embryonic kidney (HEK), Madin-Darby canine kidney
(MDCK), or Chinese hamster ovary (CHO) cells. mRNA for OAT2-tv1 and OAT2-tv2 was
demonstrated in each cell type transfected with the respective construct, indicating their
expression. OAT2-tv1 trafficked to the plasma membrane of all three cell types, but
OAT2-tv2 did not. OAT2-tv1 transported penciclovir in all three cell types, but failed
to transport para-aminohippurate, succinate, glutarate, estrone-3-sulfate, paclitaxel or
dehydroepiandrosterone sulfate – previously identified substrates of OAT2-tv2. Not
surprising given its lack of plasma membrane expression, OAT2-tv2 failed to transport
any of the organic solutes examined, including penciclovir. Penciclovir transport by
OAT2-tv1 was sensitive to large (e.g., cyclosporine A) and small (e.g., allopurinol) organic
compounds, as well as organic anions, cations and neutral compounds, highlighting
the multiselectivity of OAT2-tv1. The potencies with which indomethacin, furosemide,
cyclosporine A and cimetidine inhibited OAT2-tv1 are in good agreement with previous
studies using this variant, but inconsistent with studies using OAT2 with an unidentified
sequence. This study shows that organic molecules with diverse physicochemical
properties interact with OAT2-tv1, making it a likely site of drug interactions. Many
previously identified substrates of OAT2 are not transported by OAT2-tv1, suggesting
that variant and/or expression system may contribute. Future work should establish the
expression pattern and ligand selectivity of OAT2-tv3.
Keywords: organic anion transporter 2, transcript variant, multi-selective, drug transporter, solute carrier family,
human embryonic kidney cell, Madin-Darby canine kidney cell, Chinese hamster ovary cell
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Introduction
Organic anion transporter 2 (OAT2; SLC22A7) is a member of
the SLC22A family, and is closely related to the multi-selective
renal organic anion transporters, organic anion transporter 1
(OAT1; SLC22A6) and organic anion transporter 3 (OAT3;
SLC22A8). OAT1 and OAT3 each share ∼37% amino acid
identity with OAT2. In comparison, OAT1 and OAT3, which
have distinct but also overlapping substrate selectivity, share
∼48% amino acid sequence identity to each other. Although
OAT2 is present in the kidney, it is predominately expressed
in the liver (Sun et al., 2001; Fork et al., 2011). The ligand
selectivity and transport mechanism of OAT1 and OAT3 have
been well characterized, and much attention has been placed
on these transporters (among other select drug transporters)
since they are known to inﬂuence the pharmacokinetics of
numerous clinically relevant drugs, and because they represent
potential sites of drug–drug interactions (Giacomini et al.,
2010). In contrast, much less is known regarding the ligand
selectivity and transport mechanism of OAT2, or its role in
pharmacokinetics.
Several variants of the OAT2 peptide sequence have been
reported in the literature. Transcript variant 1 (OAT2-tv1;
GenBank accession number NP006663) and transcript variant 2
(OAT2-tv2; GenBank accession number NP696961) share 100%
amino acid sequence identity, but OAT2-tv1 is two amino
acids shorter (Cropp et al., 2008) – OAT2-tv1 and OAT2-
tv2 contain 546 and 548 amino acids, respectively. Sun et al.
(2001) also identiﬁed two transcript variants, and named them
hOAT2A and hOAT2B. hOAT2A and hOAT2B were reported
to contain 546 and 538 amino acids, respectively, and it was
suggested that they are likely alternatively spliced variants,
which contain diﬀerent C-terminal segments (Sun et al., 2001).
However, the GenBank accession number AI016020 provided for
hOAT2A and hOAT2B (Sun et al., 2001) is linked to a partial
Expressed Sequence Tag sequence, and thus, the actual peptide
sequences are unknown. Enomoto et al. (2002) reported using
an OAT2 construct that contains 539 amino acids. The peptide
sequence for this variant is deposited in the National Center
for Biotechnology Information (NCBI) database under GenBank
accession# AAG43523. For the purpose of this study, we have
denoted this construct as OAT2-tv3. Compared to OAT2-tv1,
OAT2-tv3 has a phenylalanine instead of leucine at amino acid
position 302, and the C-terminal tail is truncated, with 10 out
of its last eleven amino acids diﬀering from the corresponding
amino acids in OAT2-tv1 – this may in fact be the hOAT2B
sequence cloned by Sun et al. (2001). Supplemental Figure S1
shows an amino acid alignment of the three OAT2 sequences
identiﬁed to date.
Much of our knowledge of the ligand selectivity of OAT2
comes from studies using the cloned transporter expressed
in heterologous expression systems. Table 1 provides a
summary of studies that have examined the substrate selectivity
of OAT2, showing the OAT2 construct and heterologous
expression system used, along with the organic solutes that
were identiﬁed as substrates. Importantly, many of the studies
never cited the OAT2 sequence used, and the studies used
several diﬀerent heterologous expression systems, including S2
cells (immortalized S2 proximal tubule segment from mouse),
human embryonic kidney (HEK) cells, Madin-Darby canine
kidney (MDCK) cells and Xenopus laevis oocytes. More recent
studies (2008 and after) examining the ligand selectivity of
OAT2 have mostly used OAT2-tv1. These studies demonstrated
that OAT2-tv1 is capable of transporting select guanine-
containing antivirals (Cheng et al., 2012), creatinine (Shen
et al., 2015), orotic acid, and glutamate (Fork et al., 2011),
select antineoplastic drugs (Marada et al., 2015) and select
guanine nucleotides, including cGMP (Cropp et al., 2008)
(Table 1).
In preliminary experiments we examined the transport
of estrone-3-sulfate and para-aminohippurate by OAT2-tv1
expressed in Chinese hamster ovary (CHO) cells, and failed to
observe mediated transport, despite previous work indicating
that they are OAT2 substrates (Table 1). Since these early
studies used diﬀerent heterologous systems and possibly OAT2
variants, we hypothesized that the discrepancy could be due
to the OAT2 variant and/or heterologous expression system
used. Thus, the purpose of the present study was to examine
the ligand selectivity of OAT2 expressed in a variety of
mammalian cells, and to compare this data to previously
published data. Interestingly, while we were able to clone
OAT2-tv1 from human kidney, and obtained the OAT2-
tv2 from a commercial source, we were unsuccessful at
amplifying mRNA for OAT2-tv3 from human kidney. Thus,
we examined ligand selectivity of OAT2-tv1 and OAT2-tv2 in
three diﬀerent mammalian cell lines – CHO, HEK, and MDCK
cells.
Materials and Methods
Reagents and Chemicals
[3H]para-aminohippurate (60 Ci/mmol), [3H]estrone-3-sulfate
(50 Ci/mmol), [3H]dehydroepiandrosterone sulfate (63 Ci/
mmol), [14C]glutarate (55 mCi/mmol), and [14C]succinate
(54.0 mCi/mmol) were from American Radiochemicals (St.
Louis, MO, USA). [3H]penciclovir (1.1–18.6 Ci/mmol) and
[3H]paclitaxel (6.4 Ci/mmol) were from Moravek Biochemicals
(Brea, CA, USA). Ham’s F12K medium, Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM), fetal bovine serum (Certiﬁed,
US Origin), 1% penicillin-streptomycin solution, zeocin,
hygromycin B, Platinum High Fidelity DNA polymerase and 4–
12% Tris-glycine gels were from Life Technologies (Burlington,
ON, USA). Custom oligonucleotide primers were synthesized
by Integrated DNA Technologies (Coralville, IA, USA). The
bicinchoninic acid protein assay kit, Sulfo-NHS-SS-biotin
reagent, Streptavidin UltraLink resin and the SuperSignal R© West
Femto chemiluminescent substrate were from Thermo Scientiﬁc
(Rockford, IL, USA). All other chemicals were obtained from
Sigma–Aldrich (St. Louis, MO,USA). Human kidney cortex from
a single donor was obtained from the Eunice Kennedy Shriver
National Institute of Child Health and Human Development
(NICHD) Brain and Tissue Bank at the University of Maryland
(Baltimore, MD, USA). The use of human kidney tissue was
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TABLE 1 | Summary of studies that have examined the substrate selectivity of organic anion transporter 2 (OAT2).
Study Variant Accession number Expression system Substrates
Sun et al., 2001 ? AI016020 HEK293 para-aminohippurate, methotrexate,
cAMP, α-ketoglutarate, fluorescein
Babu et al., 2002 ? S2 cells Tetracycline, prostaglandin F2α
Enomoto et al., 2002 tv3 AF210455 S2 cells Prostaglandin F2α
Takeda et al., 2002 ? S2 cells Prostaglandin F2α, zidovudine
Kimura et al., 2002 ? S2 cells Prostaglandin E2
Khamdang et al., 2002 ? S2 cells Prostaglandin F2α, salicylate
Khamdang et al., 2003 ? S2 cells Prostaglandin F2α
Kobayashi et al., 2005a tv2 AY050498 Xenopus oocytes Estrone-3-sulfate, bumetanide,
glutarate, dehydroepiandrosterone
sulfate, allopurinol, prostaglandin E2,
5-fluorouracil, paclitaxel, ascorbate,
para-aminohippurate
Kobayashi et al., 2005b ? Xenopus oocytes Theophylline, erythromycin
Cropp et al., 2008 tv1 NM006672 HEK293 cGMP, 2’-deoxyguanosine and many
naturally occurring nucleobases,
nucleosides, and nucleotides
Cropp et al., 2008 tv2 NM153320 HEK293 Was not expressed at the plasma
membrane
Sato et al., 2010 tv3 AF210455 HEK293 Uric acid
Cheng et al., 2012 tv1 NM006672 HEK293 Penciclovir, acyclovir, ganciclovir
Fork et al., 2011 tv1 NM006672 HEK293 Orotic acid, glutamate, cGMP,
2’-deoxyguanosine, trigonelline
Lepist et al., 2014 ? Madin-Darby canine
kidney (MDCK) II
cGMP, creatinine
Shen et al., 2015 tv1 NM006672 HEK293 Penciclovir, cGMP creatinine
Marada et al., 2015 tv1 NM006672 HEK293 cGMP, irinotecan
Babelova et al., 2015 tv1 NM006672 HEK293 cGMP
The table highlights the OAT2 transcript variant and heterologous expression system used, along with the compounds that were shown to be transported.? indicates that
the OAT2 sequence used was not identified in the publication. The GenBank accession numbers shown are for the corresponding nucleotide sequences. The GenBank
accession number AI016020 refers to an Expressed Sequence Tag. The GenBank accession numbers for the peptide sequences are as follows – AY050498 (AAL12496),
AF210455 (AAG43523), NM006672 (NP006663), and NM153320 (NP696961).
approved by the Research Ethics Board of Dalhousie University.
Waymouth buﬀer (WB) used for transport experiments
contained (in mM): 135 NaCl, 28 D-glucose, 5 KCl, 1.2 MgCl2,
2.5 CaCl2, 0.8 MgSO4, and 13 HEPES-NaOH, pH 7.4. Phosphate
buﬀered saline (PBS) containing calcium and magnesium
(PBS/CM) used in biotinylation experiments contained (in mM):
137 NaCl, 2.7 KCl, 8 Na2HPO4, 0.1 CaCl2, and 1 MgCl2, pH 8.0.
Cloning of the Human Orthologs of OAT2
Transcript Variants 1 and 2
The open reading frame of the human ortholog of OAT2
transcript variant 1 (OAT2-tv1) containing 546 amino acids
was ampliﬁed from human kidney cDNA. The open reading
frame of the human ortholog of OAT2 transcript variant 2
(OAT2-tv2) containing 548 amino acids was ampliﬁed from a
construct obtained from Origene (model# SC108270, Rockville,
MD, USA) that was contained within the pCMV6-XL4 vector.
Platinum High Fidelity DNA Polymerase and sequence-speciﬁc
oligonucleotide primers were used in the polymerase chain
reaction (PCR) reactions. PCR products were puriﬁed by
gel extraction and the constructs were subcloned into the
pcDNA5/FRT/V5-His-TOPO mammalian expression plasmid
according to the manufacturer’s protocol. The constructs were
designed to contain their native stop codon. Plasmid DNA was
prepared using the MO BIO Ultra Clean plasmid preparation kit
andDNA sequencing (MCLAB, San Francisco, CA,USA) showed
that the OAT2-tv1 and OAT2-tv2 constructs corresponded to
GenBank Accession number NM006672 and GenBank Accession
number NM153320, respectively, as reported in the NCBI
database.
Cell Culture and Stable Expression of OAT2-tv1
and OAT2-tv2 Cell Lines
Chinese hamster ovary Flp-In cells were grown in medium
containing Ham’s F12 Kaighn’s modiﬁcation medium, 1%
penicillin-streptomycin, 10% fetal bovine serum and zeocin
(100 μg/ml). HEK Flp-In and MDCK Flp-In cells were grown in
DMEM containing 1% penicillin-streptomycin, 10% fetal bovine
serum and zeocin (100 μg/ml). CHO, HEK, and MDCK cell lines
stably expressing OAT2-tv1 or OAT2-tv2 were generated using
electroporation and selection as described previously (Ingraham
et al., 2014). The stable OAT2-tv1 and OAT2-tv2 cell lines were
grown in the identical medium outlined above, except that the
medium contained hygromycin B (200 μg/ml) instead of zeocin.
Cells were grown at 37◦C in a humidiﬁed atmosphere (5%
CO2/95% air).
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RNA Isolation and Reverse Transcription
Polymerase Chain Reaction (RT-PCR)
Total RNA was puriﬁed from cells using the RNeasy Mini Kit
according to the manufacturer’s instructions. RNA concentration
was determined by UV spectrophotometry. RT-PCR was
conducted using standard procedures as described previously
(Lee et al., 2015). The oligonucleotide primer sequences used
for amplifying the human ortholog of OAT2-tv1 and OAT2-
tv2 were: 5′-CATTGCAACTGAGTCCCAGTG-3′ (sense) and
5′-CAGGAGGAAGTGCAGTGGTA -3′ (antisense).
Cell Surface Biotinylation and Western Blotting
Cell surface biotinylation was conducted with cells grown
in one well of a 12-well plate. Cell surface biotinylation
was performed using Sulfo-NHS-SS-biotin (0.5 mg/ml) using
procedures identical to that described previously (Astorga et al.,
2011). The biotinylated proteins were separated on 4–12%
tris-glycine gels, and transferred to polyvinylidene diﬂuoride
membranes. The antibodies used were a polyclonal rabbit
anti-human OAT2 antibody (0.5 μg/ml) (Cosmo Bio Ltd.,
Carlsbad, CA, USA) and a goat anti-rabbit HRP-conjugated
secondary antibody (4 μg/ml). The SuperSignal West Femto
chemiluminescent (Thermo Scientiﬁc) substrate was used for
immunoreactivity detection.
Transport Studies Examining Cellular Uptake
All experiments examining cellular radiolabeled compound
uptake were conducted using cells grown to conﬂuence in 24-
well ﬂat bottom plates. The transport solution consisted of
WB (room temperature) containing radiolabeled compound
and the uptake period for all experiments was at an initial
rate time point of 5 min. [3H]Penciclovir served as the
probe OAT2 substrate. We also examined the uptake of
[3H]para-aminohippurate, [3H]estrone-3-sulfate, [14C]glutarate,
[14C]succinate, [3H]paclitaxel, and [3H]dehydroepiandrosterone
sulfate by OAT2 since published studies indicate that they are
substrates of the transport protein (Sun et al., 2001; Kobayashi
et al., 2005a). To examine the potential for compounds to
inhibit OAT2, the transport solution contained [3H]penciclovir
and either a ﬁxed concentration of test compound (1 mM),
or increasing concentrations of test compound to determine
potency of inhibition (inhibitor concentration 50, IC50). For
all cellular uptake experiments, the medium was aspirated
and the cells were rinsed once with WB (0.3 ml). Following
the uptake period, cells were washed three times with ice-
cold WB (0.5 ml each wash). After aspirating the ﬁnal wash
the cells were lysed in 0.5 N NaOH/1% SDS (0.4 ml) for
∼30 min on an orbital shaker. 1 N HCl (0.2 ml) was
then added to neutralize the NaOH, and the cell lysates
(0.5 ml) were transferred to scintillation vials containing liquid
scintillation cocktail (CytoScint ES, MP Biomedicals). Cellular
radioactivity content was determined with a Beckman LS6500
liquid scintillation counter. Protein content was determined
using the bicinchoninic acid method. See the Figure and
Table Legends for additional details describing the experimental
conditions used.
Data Analysis
Transport data are reported as the mean ± standard error of
the mean of at least three independent experiments using cells
of a diﬀerent passage number. A two-tailed unpaired Student’s
t-test was used for comparisons of means between two groups.
Signiﬁcance for all analyses was assigned at P < 0.05. All
graphing, non-linear regression analyses and statistical analyses
were performed with GraphPad Prism (version 6.03).
Results
Organic anion transporter 2-tv1 and OAT2-tv2 were individually
transfected into CHO, HEK, and MDCK cells, and placed
under selection pressure in order to establish stable cell lines.
RT-PCR analyses revealed expression of both OAT2-tv1 and
OAT2-tv2 at the mRNA level in all three cell types, indicating
successful stable expression of both constructs (Figure 1A).
However, cell surface biotinylation experiments showed that
only OAT2-tv1 was present at the cell surface (Figure 1B),
pointing to a potential traﬃcking defect associated with
OAT2-tv2.
The uptake of several putative OAT2 substrates was tested
in the three diﬀerent cell types (CHO, HEK, and MDCK)
expressing the human orthologs of either OAT2-tv1 or OAT2-
tv2 (Figure 2). Compared to parental cells, the uptake of
penciclovir was 21-fold, 39-fold, and 5-fold signiﬁcantly higher in
CHO-OAT2-tv1, HEK-OAT2-tv1, and MDCK-OAT2-tv1 cells,
respectively (Figure 2A). Consistent with its lack of cell surface
expression, the uptake of penciclovir into CHO-OAT2-tv2,
HEK-OAT2-tv2, and MDCK-OAT2-tv2 cells was not diﬀerent
from uptake into the respective parental cells (Figure 2A).
The uptake of para-aminohippurate (Figure 2B), estrone-3-
sulfate (Figure 2C), or glutarate (Figure 2D) into CHO, HEK,
and MDCK cells expressing either OAT2-tv1 or OAT2-tv2 was
not diﬀerent than uptake into the respective parental cells.
FIGURE 1 | mRNA expression (A) and cell surface protein expression
(B) of Organic anion transporter 2 (OAT2)-tv1 (tv1) or OAT2-tv2 (tv2) in
Chinese hamster ovary (CHO), human embryonic kidney (HEK), or
Madin-Darby canine kidney (MDCK) cells stably transfected with the
respective construct, or in parental cells (P). mRNA expression was
determined by reverse transcription polymerase chain reaction (RT-PCR) using
oligonucleotide primers against OAT2. Amplified products were separated on
1% agarose gels and stained with ethidium bromide. Sulfo-NHS-SS-biotin
was used for cell surface biotinylation.
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FIGURE 2 | Cellular accumulation of [3H]penciclovir (A), [3H]para-aminohippurate (B), [3H]estrone-3-sulfate (C), or [14C]glutarate (D) by parental
CHO, HEK, or MDCK cells, or CHO, HEK, or MDCK cells stably expressing either OAT2-tv1 or OAT2-tv2. The concentration of [3H]penciclovir in the
transport solution was 0.1 μM for CHO and MDCK cell experiments, and 0.5 μM for HEK cell experiments. The concentrations of [3H]para-aminohippurate,
[3H]estrone-3-sulfate and [14C]glutarate were 8 nM, 10 nM, and 18 μM, respectively. Uptake was conducted for 5 min at room temperature. Values are
mean ± standard error of the mean of four experiments. ∗Significantly different from parental cells, P < 0.05, two-tailed unpaired student’s t-test.
Additionally, when expressed in CHO cells, OAT2-tv1 was
unable to show mediated transport of two other putative OAT2
substrates, dehydroepiandrosterone sulfate and paclitaxel. The
cellular accumulation of [3H]dehydroepiandrosterone sulfate
(12 nM) into CHO parental vs. CHO-OAT2-tv1 cells was
10.3 ± 1.1 fmoles mg protein−1 · min−1 vs. 11.0 ± 0.54 fmoles
· mg protein−1 · min−1, respectively (n = 3). The cellular
accumulation of [3H]paclitaxel (22 nM) into CHO parental vs.
CHO-OAT2-tv1 cells was 89± 3.8 fmoles ·mg protein−1 ·min−1
vs. 90 ± 5.1 fmoles · mg protein−1 · min−1 (n = 3). Given
the similarity in substrate selectivity of OAT2-tv1 regardless of
cell type, and the lack of functional expression of OAT2-tv2,
all subsequent experiments were done with the CHO-OAT2-tv1
cells.
It was previously reported that succinate and fumarate are
capable of trans-stimulating OAT2-mediated substrate uptake
(Kobayashi et al., 2005a), suggesting that OAT2 may be an
organic anion/dicarboxylate exchanger. Given these previous
results we hypothesized that if dicarboxylates interact as
substrates of OAT2 that they may also inhibit the transport
protein. Thus, we examined the ability of a variety of Kreb’s cycle
intermediates (succinate, fumarate, α-ketoglutarate, oxaloacetate,
citrate, cis-aconitate, and D-malate) to cis-inhibit penciclovir
uptake into CHO-OAT2-tv1 cells. Even at a high concentration
(1 mM), none of the Kreb’s cycle intermediates tested,
including succinate and fumarate, cis-inhibited penciclovir
uptake (Figure 3). Conversely, the OAT2 inhibitors glutamate
(1 mM) and furosemide (200 μM) reduced penciclovir uptake
by 70–85% compared to control, conﬁrming that OAT2-tv1
was functional (Figure 3). We also examined the uptake of
[14C]-succinate by CHO-OAT2-tv1 cells to determine if it is
in fact a substrate. The uptake of [14C]succinate by CHO-
OAT2-tv1 cells was not diﬀerent than uptake into the parental
CHO cells (Figure 4). In a single experiment (n = 1), the
uptake of [14C]succinate by CHO cells stably expressing the Na-
dicarboxylate cotransporter 3 (NaDC3) was∼30-fold higher than
control.
Given the results that previously identiﬁed substrates (para-
aminohippurate, estrone-3-sulfate, glutarate, dehydroepiandro-
sterone sulfate, paclitaxel, and succinate) were not transported
by OAT2-tv1 in the present study led us to examine the
inhibitory potential of a variety of drugs (organic anions, cations,
and neutral molecules) against OAT2-tv1. A total of seventeen
compounds with diverse physicochemical properties were tested
for their potency to inhibit penciclovir uptake by CHO-OAT2-
tv1 cells (Table 2). The majority of organic anions tested were
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FIGURE 3 | Cis-inhibition of [3H]penciclovir (∼30 nM) uptake into
CHO-OAT2-tv1 cells by Kreb’s cycle intermediates. The concentration of
each Kreb’s cycle intermediate was 1 mM. Uptake was conducted for 5 min.
Glutamate (1 mM) or furosemide (200 μM) were used as positive control
inhibitors. Values are the mean ± standard error of the mean from 3 to 4
experiments. ∗Significantly different from control (open bar), P < 0.05,
two-tailed unpaired Student’s t-test.
FIGURE 4 | Cellular accumulation of [14C]succinate (18.5 µM) by CHO
parental cells, CHO-OAT2-tv1 cells or CHO cells stably expressing the
Na-dicarboxylate cotransporter 3 (NaDC3). Uptake was conducted for
5 min. Values are the mean ± standard error of the mean of four experiments
for CHO parental and CHO-OAT2-tv1 cells. A single uptake experiment was
performed with CHO-NaDC3 cells. There was no significant difference in
[14C]succinate uptake by CHO-OAT2-tv1 cells compared to parental CHO
cells (P > 0.05, two-tailed unpaired student’s t-test.
eﬀective inhibitors, reducing penciclovir uptake by ≥85% of the
control level. These compounds inhibited with varying degrees
of potency ranging from 3.7 μM (indomethacin) to 210 μM
(para-aminohippurate). Methotrexate (76%), probenecid (64%),
and cidofovir (53%) were also capable of reducing OAT2-
tv1-mediated penciclovir uptake, but the eﬀect was not dose-
dependent, so IC50 values could not be determined. The organic
cations and neutral compounds also showed varying abilities
TABLE 2 | Potency of OAT2-tv1 inhibition by organic molecules with
diverse physicochemical properties.
Test compound Maximum
concentration
(µM)
%
Inhibition
IC50 (µM) MW
Organic anions
Indomethacin 1000 99 3.7 ± 0.5 357.8
Repaglinide 500 99 30.0 ± 3.6 452.6
para-aminohippurate 1000 99 210.3 ± 77 194.2
Telmisartan 200 96 17.1 ± 1.3 514.6
Prostaglandin E2 500 96 26.8 ± 2.4 352.5
Estrone Sulfate 1000 95 36.1 ± 3.9 372.4
Furosemide 200 90 10.8 ± 1.5 330.7
Valsartan 1000 86 126.9 ± 29 435.5
Methotrexate 1000 76 ND 454.4
Probenecid 1000 64 ND 285.4
Cidofovir 1000 53 ND 279.2
Organic cations
Cimetidine 1000 95 57.2 ± 14 252.3
Erythromycin 1000 65 12.0 ± 5.4 733.9
Cyclosporin A 62.5 55 8.6 ± 4.9 1202.6
Tetrapentylammonium 1000 49 278.8 ± 142 378.5
Tetraethylammonium 1000 42 54.3 ± 33 210.2
Neutral compounds
Allopurinol 1000 95 70.1 ± 34 136.1
Penciclovir 1500 85 78.4 ± 8.2 253.3
[3H] Penciclovir (∼30 nM) was the substrate. Uptake was conducted for 5 min at
room temperature in the presence of increasing concentrations of test compound.
The maximum concentration of test compound used is indicated. The potency of
inhibition (IC50 determination) was determined by non-linear regression analysis.
IC50 values are the mean ± standard error of the mean of 3–4 experiments. The %
inhibition corresponds to the percent reduction in transport, compared to parental
cells, that was achieved by the maximum drug concentration tested. ND, the IC50
could not be determined by non-linear regression analysis. MW, test compound
molecular weight (grams/mol).
to inhibit OAT2-tv1. Notably, cimetidine and allopurinol each
inhibited 95% of transport activity, with IC50 values of 57 and
70 μM, respectively.
Discussion
In the present study we cloned and stably expressed OAT2-
tv1 and OAT2-tv2 in three diﬀerent mammalian cell lines in
order to examine their ligand selectivity. Unexpectedly, several
attempts to amplify OAT2-tv3 mRNA from human kidney were
unsuccessful. OAT2-tv3 was cloned by Enomoto et al. (2002),
and in their manuscript they reference GenBank accession#
AF210455 as the corresponding nucleotide sequence. According
to NCBI, this OAT2 construct was originally cloned from human
kidney with the authorship listed as: Reid G, Bahn A, Ebbinghaus
C, Wolﬀ NA, and Burckhardt G (deposited in 2001). Also of
interest, there are several studies that have examined the ligand
selectivity of OAT2, where the sequence used was not cited
[(Sun et al., 2001; Babu et al., 2002; Khamdang et al., 2002,
2003; Kimura et al., 2002; Takeda et al., 2002; Kobayashi et al.,
2005b; Lepist et al., 2014);Table 1]. Like the Enomoto et al. (2002)
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study that described the cloning of OAT2-tv3, most of these other
studies had the same senior author, suggesting that OAT2-tv3
may have been used in these other studies as well. However, since
the exact sequence used was not cited in these manuscripts, we
cannot be certain that this is the case.
OAT2-tv3 shares 97% sequence identity with OAT2-tv1
and OAT2-tv2. The OAT2-tv3 amino acid sequence diﬀers
from OAT2-tv1 and OAT2-tv2 primarily in its C-terminal end
(Supplemental Figure S1). Amino acid alignment of OAT2 from
human (OAT2-tv1 and OAT2-tv3), mouse, rat, rabbit, cattle,
pig, horse, opossum, and chicken indicates that the C-terminal
end varies across species as well (Supplemental Figure S2).
Interestingly, there are a greater number of conserved amino
acids at homologous positions in the C-terminal of OAT2 from
other species (except mouse) and OAT2-tv1, than with OAT2-
tv3 (Supplemental Figure S2). A BLAST search of the human
genome in NCBI using the OAT2-tv3 cDNA sequence as the
query results in OAT2-tv1 and OAT2-tv2 as hits, but not OAT2-
tv3. The OAT2-tv3 sequence was also not found in the NHLBI
Exome Sequencing Project Exome Variant Server database
(http://evs.gs.washington.edu/EVS/). Future studies should be
directed at determining if OAT2-tv3 actually exists, and if so,
its tissue, cellular and subcellular distribution, as well as how its
sequence variation aﬀects ligand selectivity.
When expressed in either CHO, MDCK, or HEK cells,
OAT2-tv2 was non-functional. While OAT2-tv2 expression at
the mRNA level in each of the cell lines was detected, cell
surface biotinylation experiments indicated that the protein was
not present at the plasma membrane, unlike OAT2-tv1, which
showed clear plasma membrane expression. OAT2-tv2 has an
additional serine and glutamine at amino acid positions 132
and 133, respectively. Homology modeling was previously used
to predict the tertiary structure of OAT1 (Perry et al., 2006),
which is related to OAT2. Supplemental Figure S3 shows an
amino acid alignment between the ﬁrst ∼200 amino acids of
OAT1, OAT2-tv1, and OAT2-tv2. The ﬁgure highlights the
position of transmembrane helices 1 and 2, as well as the
long extracellular loop in the OAT1 model. Assuming similar
topologies between OAT1 and OAT2, the additional two amino
acids in OAT2-tv2 are expected to occur in the long extracellular
loop between transmembrane helices 1 and 2 (Supplemental
Figure S3) – these two amino acids were also predicted to be in
the putative long extracellular loop of OAT2 using HMMTOP
2.0. Several studies have shown that modiﬁcation of amino
acids in the long extracellular loop of OAT1 (as well as other
related SLC drug transporters) has a profound inﬂuence on
its plasma membrane expression (Tanaka et al., 2004a,b), and
given these results, the insertion of two additional amino acids
in the long loop of OAT2 may aﬀect its protein folding and
traﬃcking. Consistent with this hypothesis, Cropp et al. (2008)
showed by immunocytochemistry that OAT2-tv2 protein in HEK
cells is retained in an intracellular compartment. Alternatively,
the OAT2-tv2 variant may have an increased rate of protein
degradation (Cropp et al., 2008). While OAT2-tv2 shows no
apparent expression at the plasma membrane of any mammalian
cell tested to date, it was clearly expressed and functional in
X. laevis oocytes (Kobayashi et al., 2005a) (Table 1). This raises
the question of the most appropriate heterologous system for
studying mammalian transport proteins, and what the functional
role, if any, OAT2-tv2 has in human tissues. Cropp et al. (2008)
showed that mRNA for OAT2-tv2 is expressed at similar levels
to OAT2-tv1 in a variety of tissues. Perhaps OAT2-tv2 has a role
in transporting its substrates across intracellular membranous
compartments.
Several early studies that have helped deﬁne the substrate
selectivity of human OAT2 were done using a construct
with an undeﬁned sequence or OAT2-tv2 expressed in
Xenopus oocytes (Table 1), which is non-functional in all
mammalian cells tested to date. In particular, early studies
have suggested that para-aminohippurate, estrone-3-sulfate,
glutarate, dehydroepiandrosterone sulfate, paclitaxel, among
others, are human OAT2 substrates (Table 1). Importantly,
according to nearly all reviews on organic anion transport,
the aforementioned compounds are listed as substrates of
human OAT2 [e.g., (Vanwert et al., 2010)]. Yet, we showed that
OAT2-tv1 does not transport these organic anions in the cell
types tested, but did transport penciclovir in all three cell types.
Together, these data indicate that the substrate selectivity of
OAT2-tv1 is similar in CHO, HEK, and MDCK cells. Cropp
et al. (2008) also failed to observe appreciable uptake of para-
aminohippurate by HEK-OAT2-tv1 cells. Also consistent with
our results, Sun et al. (2001) did not observe transport of
dehydroepiandrosterone sulfate by OAT2 – although it is unclear
what variant was used in their study. Despite not observing
transport of para-aminohippurate, estrone-3-sulfate, glutarate,
dehydroepiandrosterone sulfate, or paclitaxel, we did show
robust transport of penciclovir by OAT2-tv1, which has been
demonstrated previously (Cheng et al., 2012; Shen et al., 2015).
When expressed in S2 cells, OAT2 (sequence not given) failed
to transport acyclovir or ganciclovir (Takeda et al., 2002), yet,
these antivirals, along with penciclovir, are clearly substrates
of OAT2-tv1 (Cheng et al., 2012). Interestingly, most recent
studies examining ligand selectivity of OAT2 have used transcript
variant 1, as opposed to the other variants (Table 1).
Information regarding the transport mechanism of OAT2 is
limited to only a few studies that used either human, mouse
or rat orthologs of OAT2. Transport by all three orthologs is
Na-independent (Sekine et al., 1998; Kobayashi et al., 2002,
2005a). Fork et al. (2011) showed that OAT2-tv1 in HEK cells
can mediate orotic acid/orotic acid and orotic acid/glutamate
exchange. Uptake of estrone-3-sulfate by OAT2-tv2 in Xenopus
oocytes was modestly stimulated by pre-loading the oocytes
with 5 mM fumarate (1.7-fold stimulation) or succinate (2.1-
fold), suggesting an anion exchange mechanism involving either
of these Kreb’s cycle intermediates (Kobayashi et al., 2005a).
In contrast, Sato et al. (2010) failed to observe stimulation
of urate uptake by OAT2-tv3 in HEK cells pre-loaded with
succinate (100 mM). Given these discrepancies with succinate,
we tested the cis-inhibitory eﬀect of a variety of Kreb’s cycle
intermediates (including fumarate and succinate) with OAT2-
tv1. However, none of the Kreb’s cycle intermediates tested (at
1 mM) inhibited transport of penciclovir by OAT2-tv1. Similar to
our results, Babelova et al. (2015) did not observe cis-inhibition of
OAT2-tv1-mediated cGMP transport by citrate or cis-aconitate.
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We further showed that, indeed, [14C]succinate is not
transported by OAT2-tv1 in CHO cells. Our data, along with
those of Sato et al. (2010), suggest that at least succinate is not
translocated by OAT2-tv1. This raises the question – what is
the driving force for OAT2-mediated substrate uptake into cells?
Glutamate is an abundant intracellular amino acid (2–20 mM;
Newsholme et al., 2003), and Fork et al. (2011) showed that
the outwardly directed glutamate gradient can stimulate OAT2-
tv1-mediated substrate uptake via an exchange mechanism.
Thus, as previously suggested (Fork et al., 2011), glutamate
is a good candidate for a physiological trans-substrate for
OAT2-tv1-mediated translocation.
Given that several previously identiﬁed substrates were not
transported by OAT2-tv1 in the present study, we also examined
the inhibitory potential of a variety of organic compounds against
OAT2-tv1. To our knowledge, many of the compounds tested
have not been previously examined for their inhibition potency
against OAT2, including repaglinide, para-aminohippurate,
telmisartan, estrone-3-sulfate, valsartan, methotrexate, cidofovir,
tetrapentylammonium, tetraethylammonium, and allopurinol.
The IC50 values that we obtained for inhibition of OAT2-tv1
by indomethacin (3.7 μM), furosemide (10.8 μM), cyclosporine
A (8.6 μM), and cimetidine (57.2 μM) are in good agreement
with other studies examining the potency with which these
compounds inhibit OAT2-tv1 – indomethacin [2.1 μM; (Shen
et al., 2015)], furosemide [10.9 μM; (Babelova et al., 2015)],
cyclosporine A [11.1 μM; (Shen et al., 2015)], and cimetidine
[62.3; (Shen et al., 2015)]. In contrast, there is an inconsistency
between our data and studies examining the inhibitory
potency of several of these compounds against OAT2 with an
unidentiﬁed sequence – indomethacin [64.1 μM; (Khamdang
et al., 2002)], furosemide [603 μM; (Hasannejad et al., 2004)]
and cimetidine [no inhibition; (Khamdang et al., 2004)]. Also
at odds is the observation that allopurinol is a substrate
(Cropp et al., 2008) and inhibitor (present study) of OAT2-
tv1, but did not inhibit uric acid transport by OAT2-tv3 in
HEK293 cells (Sato et al., 2010). Our data also showed that
transport of penciclovir by OAT2-tv1 is sensitive to large (e.g.,
cyclosporine A) and small (e.g., allopurinol) organic compounds,
and organic anions, cations as well as neutral compounds,
highlighting the multiselectivity of the OAT2-tv1 ligand binding
surface.
In summary, data from the literature on ligand selectivity
of OAT2 is complicated by the fact that there are apparently
three transcript variants, and many of the studies failed
to identify the transcript variant that was used. Previously
identiﬁed substrates of OAT2-tv2 expressed in Xenopus oocytes,
including para-aminohippurate, succinate, glutarate, estrone-3-
sulfate, paclitaxel, or dehydroepiandrosterone sulfate, are not
transported by OAT2-tv1. For the limited number of compounds
tested, the substrate selectivity of OAT2-tv1 was qualitatively
similar regardless of the cell type in which it was expressed.
Interestingly, OAT2-tv2 did not express at the plasma membrane
of any of the three mammalian cell types examined. There was
also a discrepancy between potency of several compounds to
inhibit OAT2-tv1 in the present study, and previously published
data using OAT2 with an unidentiﬁed sequence. OAT2-tv1
was inhibited by compounds with diverse physicochemical
properties, making it a potential site of drug–drug interactions.
Future studies using OAT2 for ligand interaction studies should
identify the transcript variant being used. Additional studies
are required to determine the expression pattern and functional
activity of OAT2-tv3.
Author Contributions
Participated in research design: RP and AH.
Conducted experiments: AH and LB.
Performed data analysis: AH and LB.
Wrote or contributed to the writing of the manuscript: RP
and AH.
Funding
This work was supported by the Canadian Institutes of Health
Research [Grant 286509], the Nova Scotia Health Research
Foundation [Grant MED-EST-2013-9003], and the Natural
Sciences and Engineering Research Council of Canada [Grant
RGPIN/418243-2012].
Acknowledgment
We are grateful to Ana M. Pajor of UCSD for providing the
pcDNA3.1 plasmid containing NaDC3.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphar.
2015.00216
References
Astorga, B., Wunz, T. M., Morales, M., Wright, S. H., and Pelis,
R. M. (2011). Diﬀerences in the substrate binding regions of
renal organic anion transporters 1 (OAT1) and 3 (OAT3). Am. J.
Physiol. Renal Physiol. 301, F378–F386. doi: 10.1152/ajprenal.00735.
2010
Babelova, A., Burckhardt, B. C., Wegner, W., Burckhardt, G., and Henjakovic, M.
(2015). Sex-diﬀerences in renal expression of selected transporters and
transcription factors in lean and obese Zucker spontaneously hypertensive fatty
rats. J. Diabetes Res. 2015, 483238. doi: 10.1155/2015/483238
Babu, E., Takeda, M., Narikawa, S., Kobayashi, Y., Yamamoto, T., Cha, S. H.,
et al. (2002). Human organic anion transporters mediate the transport of
tetracycline. Jpn. J. Pharmacol. 88, 69–76. doi: 10.1254/jjp.88.69
Cheng, Y., Vapurcuyan, A., Shahidullah, M., Aleksunes, L. M., and Pelis, R. M.
(2012). Expression of organic anion transporter 2 in the human kidney and its
potential role in the tubular secretion of guanine-containing antiviral drugs.
Drug Metab. Dispos. 40, 617–624. doi: 10.1124/dmd.111.042036
Frontiers in Pharmacology | www.frontiersin.org 8 October 2015 | Volume 6 | Article 216
Hotchkiss et al. OAT2 has broad ligand selectivity
Cropp, C. D., Komori, T., Shima, J. E., Urban, T. J., Yee, S. W., More, S. S., et al.
(2008). Organic anion transporter 2 (SLC22A7) is a facilitative transporter of
cGMP.Mol. Pharmacol. 73, 1151–1158. doi: 10.1124/mol.107.043117
Enomoto, A., Takeda, M., Shimoda, M., Narikawa, S., Kobayashi, Y., Kobayashi, Y.,
et al. (2002). Interaction of human organic anion transporters 2 and 4 with
organic anion transport inhibitors. J. Pharmacol. Exp. Ther. 301, 797–802. doi:
10.1124/jpet.301.3.797
Fork, C., Bauer, T., Golz, S., Geerts, A., Weiland, J., Del, T. D., et al. (2011). OAT2
catalyses eﬄux of glutamate and uptake of orotic acid. Biochem. J. 436, 305–312.
doi: 10.1042/BJ20101904
Giacomini, K.M., Huang, S.M., Tweedie,D. J., Benet, L. Z., Brouwer, K. L., Chu, X.,
et al. (2010). Membrane transporters in drug development. Nat. Rev. Drug
Discov. 9, 215–236. doi: 10.1038/nrd3028
Hasannejad, H., Takeda, M., Taki, K., Jung, S. H., Babu, E., Jutabha, P.,
et al. (2004). Interactions of human organic anion transporters with
diuretics. J. Pharmacol. Exp. Ther. 308, 1021–1029. doi: 10.1124/jpet.103.
059139
Ingraham, L., Li, M., Renfro, J. L., Parker, S., Vapurcuyan, A., Hanna, I., et al.
(2014). A plasma concentration of alpha-ketoglutarate inﬂuences the kinetic
interaction of ligands with organic anion transporter 1. Mol. Pharmacol. 86,
86–95. doi: 10.1124/mol.114.091777
Khamdang, S., Takeda, M., Babu, E., Noshiro, R., Onozato, M. L., Tojo, A., et al.
(2003). Interaction of human and rat organic anion transporter 2 with various
cephalosporin antibiotics. Eur. J. Pharmacol. 465, 1–7. doi: 10.1016/S0014-
2999(03)01381-5
Khamdang, S., Takeda, M., Noshiro, R., Narikawa, S., Enomoto, A., Anzai, N., et al.
(2002). Interactions of human organic anion transporters and human organic
cation transporters with nonsteroidal anti-inﬂammatory drugs. J. Pharmacol.
Exp. Ther. 303, 534–539. doi: 10.1124/jpet.102.037580
Khamdang, S., Takeda, M., Shimoda, M., Noshiro, R., Narikawa, S., Huang,
X. L., et al. (2004). Interactions of human- and rat-organic anion transporters
with pravastatin and cimetidine. J. Pharmacol. Sci. 94, 197–202. doi:
10.1254/jphs.94.197
Kimura, H., Takeda, M., Narikawa, S., Enomoto, A., Ichida, K., and Endou, H.
(2002). Human organic anion transporters and human organic cation
transporters mediate renal transport of prostaglandins. J. Pharmacol. Exp. Ther.
301, 293–298. doi: 10.1124/jpet.301.1.293
Kobayashi, Y., Ohshiro, N., Sakai, R., Ohbayashi, M., Kohyama, N., and
Yamamoto, T. (2005a). Transport mechanism and substrate speciﬁcity of
human organic anion transporter 2 (hOat2 [SLC22A7]). J. Pharm. Pharmacol.
57, 573–578. doi: 10.1211/0022357055966
Kobayashi, Y., Sakai, R., Ohshiro, N., Ohbayashi, M., Kohyama, N., and
Yamamoto, T. (2005b). Possible involvement of organic anion transporter 2
on the interaction of theophylline with erythromycin in the human liver. Drug
Metab. Dispos. 33, 619–622. doi: 10.1124/dmd.104.003301
Kobayashi, Y., Ohshiro, N., Shibusawa, A., Sasaki, T., Tokuyama, S., Sekine, T.,
et al. (2002). Isolation, characterization and diﬀerential gene expression of
multispeciﬁc organic anion transporter 2 in mice. Mol. Pharmacol. 62, 7–14.
doi: 10.1124/mol.62.1.7
Lee, J., Shahidullah, M., Hotchkiss, A., Coca-Prados, M., Delamere, N. A., and
Pelis, R. M. (2015). A renal-like organic anion transport system in the ciliary
epithelium of the bovine and human eye. Mol. Pharmacol. 87, 697–705. doi:
10.1124/mol.114.096578
Lepist, E. I., Zhang, X., Hao, J., Huang, J., Kosaka, A., Birkus, G., et al. (2014).
Contribution of the organic anion transporter OAT2 to the renal active tubular
secretion of creatinine and mechanism for serum creatinine elevations caused
by cobicistat. Kidney Int. 86, 350–357. doi: 10.1038/ki.2014.66
Marada, V. V., Florl, S., Kuhne, A., Muller, J., Burckhardt, G., and Hagos, Y.
(2015). Interaction of human organic anion transporter 2 (OAT2) and sodium
taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs.
Pharmacol. Res. 91, 78–87. doi: 10.1016/j.phrs.2014.11.002
Newsholme, P., Procopio, J., Lima, M. M., Pithon-Curi, T. C., and Curi, R. (2003).
Glutamine and glutamate–their central role in cell metabolism and function.
Cell Biochem. Funct. 21, 1–9. doi: 10.1002/cbf.1003
Perry, J. L., Dembla-Rajpal, N., Hall, L. A., and Pritchard, J. B. (2006). A three-
dimensional model of human organic anion transporter 1: aromatic amino
acids required for substrate transport. J. Biol. Chem. 281, 38071–38079. doi:
10.1074/jbc.M608834200
Sato, M., Mamada, H., Anzai, N., Shirasaka, Y., Nakanishi, T., and Tamai, I. (2010).
Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in
human. Biol. Pharm. Bull. 33, 498–503. doi: 10.1248/bpb.33.498
Sekine, T., Cha, S. H., Tsuda, M., Apiwattanakul, N., Nakajima, N., Kanai, Y., et al.
(1998). Identiﬁcation of multispeciﬁc organic anion transporter 2 expressed
predominantly in the liver. FEBS Lett. 429, 179–182. doi: 10.1016/S0014-
5793(98)00585-7
Shen, H., Liu, T., Morse, B. L., Zhao, Y., Zhang, Y., Qiu, X., et al. (2015).
Characterization of organic anion transporter 2 (SLC22A7): a highly eﬃcient
transporter for creatinine and species-dependent renal tubular expression.Drug
Metab. Dispos. 43, 984–993. doi: 10.1124/dmd.114.062364
Sun, W., Wu, R. R., van Poelje, P. D., and Erion, M. D. (2001). Isolation of a family
of organic anion transporters from human liver and kidney. Biochem. Biophys.
Res. Commun. 283, 417–422. doi: 10.1006/bbrc.2001.4774
Takeda, M., Khamdang, S., Narikawa, S., Kimura, H., Kobayashi, Y., Yamamoto, T.,
et al. (2002). Human organic anion transporters and human organic cation
transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. 300,
918–924. doi: 10.1124/jpet.300.3.918
Tanaka, K., Xu, W., Zhou, F., and You, G. (2004a). Role of glycosylation in
the organic anion transporter OAT1. J. Biol. Chem. 279, 14961–14966. doi:
10.1074/jbc.M400197200
Tanaka, K., Zhou, F., Kuze, K., and You, G. (2004b). Cysteine residues in
the organic anion transporter mOAT1. Biochem. J. 380, 283–287. doi:
10.1042/bj20031724
Vanwert, A. L., Gionfriddo, M. R., and Sweet, D. H. (2010). Organic
anion transporters: discovery, pharmacology, regulation and roles in
pathophysiology. Biopharm. Drug Dispos. 31, 1–71. doi: 10.1002/bdd.693
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Hotchkiss, Berrigan and Pelis. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 9 October 2015 | Volume 6 | Article 216
